Safety of apremilast: risk of psychical disorders
Abstract
Apremilast is a new selective inhibitor of phosphodiesterase 4 (PDE4) of the class of small molecules, approved for treatment of psoriatic arthritis and psoriasis. The efficacy and safety of apremilast in the treatment of moderate to severe plaque psoriasis have been demonstrated in multicenter, randomized, double-blind, placebo-controlled clinical trials of ESTEEM 1 and ESTEEM 2 (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis). These studies describe adverse reactions such as mental disorders: depression, suicidal thoughts, suicidal behavior. However, data on the increase in the incidence of these adverse reactions during longer treatment with apremilast were not obtained. The article presents the reports from the UK regulator (MHRA) and international database VigiBase on the increased risk of developing suicidal thoughts, suicide attempts, completed suicides and suicidal behavior during treatment with apremilast.
Keywords
ингибиторы фосфодиэстеразы 4,
препараты класса малых молекул,
апремиласт,
нарушения психики,
суицидальные мысли,
суицидальные наклонности,
суицидальное поведение,
inhibitors of phosphodiesterase 4,
Aprimilast,
psychical disorders,
suicidal ideation,
suicide attempt,
completed suicide,
suicidal behavior
About the Authors
T. M. Bukatina
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
N. Yu. Velts
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
M. A. Darmostukova
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
E. Yu. Pasternak
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
T. V. Romanova
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
References
1. Astakhova AV, Lepakhin VC. Adverse Reactions and Control of DragSafety: A Guide to Pharmacovigilance. Moscow: Kogito-Center; 2004.
2. Olefir SE, Verlan NV, Romanov BC, Dvojnikova NA, Kochkina EO. Problems monitoring the safety of pharmacotherapy. Moscow: Folium, 2017.
3. Zhuravleva MV, Kukes VG, Prokofiev AB, Arkhipov VV, Olefir YuV, Serebrova SYu, et al. Efficacy and safety of medicines: the value and opportunities of clinical pharmacology. The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal products 2015; (2): 20 — 24.
4. Fala L. Otezla (Apremilast), an Oral PDE-4 Inhibitor, Receives FDA Approval for the Treatment of Patients with Active Psoriatic Arthritis and Plaque Psoriasis. American Health Drug Benefits. 2015 Mar; 8(Spec Feature): 105–110.
5. Young M, Heather L. Roebuck. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor: A novel treatment option for nurse practitioners treating patients with psoriatic disease. Jounal of the American Association of Nurse Practitioners. 2016 Dec; 28(12): 683–695.
6. Dattola A, Del Duca E, Saraceno R, Gramiccia T, Bianchi L. Safety evaluation of apremilast for the treatment of psoriasis. Expert Opin Drug Saf. 2017 Mar; 16(3): 381–385.
7. Gisondi P, Girolomoni G. Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis. Drug Design, Development and Therapy. 2016; 10: 1763–1770.
8. Torres T, Puig L. Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis. Am J Clin Dermatol. 2017 Jun 8.
9. Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodi-esterase 4 inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (ESTEEM 1) J Am Acad Dermatol. 2015; 73: 37–49.
10. Reich K, Papp K, Gordon K, et al. Long-term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis of two phase 3, randomized, controlled trials (ESTEEM 1 and 2); Presented at: Annual Congress of the European Academy of Dermatology and Venereology; October 8–12, 2014; Amsterdam, The Netherlands.
11. Letters sent to healthcare professionals in November 2016 (14.12.2016 ã.). [Electronic resource]: URL: https://www.gov.uk/drug-safety-update.
Review
For citations:
Bukatina T.M., Velts N.Yu., Darmostukova M.A., Pasternak E.Yu., Romanova T.V. Safety of apremilast: risk of psychical disorders. Safety and Risk of Pharmacotherapy. 2017;5(4):182-187. (In Russ.)
Views:
1249
Email this article 